The role of established and emerging risk factors in peripheral vascular graft occlusion

Bibliography

• TAYLOR SM, KALBAUGH CA, BLACKHURST DW et al.: Determinants of functional outcome after revascularization for critical limb ischaemia: an analysis of 1000 consecutive vascular interventions. J. Vasc. Surg. (2006) 44:745-755
   Google Scholar
• AWAD S, KARKOS CD, SERRACHINO-INGLOTT F et al.: The impact of diabetes on current revascularization practice and clinical outcome in patients with critical lower limb ischaemia. Eur. J. Vasc. Endovasc. Surg. (2006) 32:51-59.
   PubMed Web of Science ®Google Scholar
• CONTE MS, LORENZ TJ, NADYK DF, CLOWES AW, MONETA GL, SEELY BL: Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal graft failure. Vasc Endovascular Surg. (2005) 39:15-23.
   Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive Summary of The Third Report of The National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
   PubMed Web of Science ®Google Scholar
• SMITH SC Jr, ALLEN J, BLAIR SN et al.; AHA/ACC; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 113:2363-2372.
   PubMed Web of Science ®Google Scholar
• LIPPI G, VERALDI GF, DORUCCI V et al.: Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery. Scand. J. Clin. Lab. Invest. (1998) 58:497-504.
   Google Scholar
• ABBRUZZESE TA, HAVENS J, BELKIN M et al.: Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J. Vasc. Surg. (2004) 39:1178-1185.
   PubMed Web of Science ®Google Scholar
• HENKE PK, BLACKBURN S, PROCTOR MC et al.: Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J. Vasc. Surg. (2004) 39:357-365.
   PubMed Web of Science ®Google Scholar
• The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary artery Bypass Graft Trial Investigators. N. Engl. J. Med. (1997) 336:153-162.
   PubMed Web of Science ®Google Scholar
• WILLIGENDAEL EM, TEIJINK JA, BARTELINK ML, PETERS RJ, BULLER HR, PRINS MH: Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J. Vasc. Surg. (2005) 42:67-74.
   PubMed Web of Science ®Google Scholar
• TSIARA S, ELISAF M, MIKHAILIDIS DP: Influence of smoking on predictors of vascular disease. Angiology (2003) 54:507-530.
   PubMed Web of Science ®Google Scholar
• AMELI FM, STEIN M, PROVAN JL, PROSSER R: The effect of postoperative smoking on femoropopliteal bypass grafts. Ann. Vasc. Surg. (1989) 3:20-25.
   PubMedGoogle Scholar
• HERRING M, GARDNER A, GLOVER J: Seeding human arterial prostheses with mechanically derived endothelium. The detrimental effect of smoking. J. Vasc. Surg. (1984) 1:279-289.
   PubMed Web of Science ®Google Scholar
• POWELL JT, GREENHALGH RM: Smoking and factors influencing the outcome of arterial reconstruction. Ann. Chir. Gynaecol. (1992) 81:236-241.
   PubMedGoogle Scholar
• POWELL JT, GREENHALGH RM: Changing the smoking habit and its influence on the management of vascular disease. Acta Chir. Scand. Suppl. (1990) 555:99-103.
   Google Scholar
• PROVAN JL, SOJKA SG, MURNAGHAN JJ, JAUNKALNS R: The effect of cigarette smoking on the long-term success rates of aortofemoral and femoropopliteal reconstructions. Surg. Gynecol. Obstet. (1987) 165:49-52.
   Web of Science ®Google Scholar
• MII S, MORI A, SAKATA H, KAWAZOE N: Reoperation for graft failure of femoropopliteal bypass with externally supported knitted Dacron prosthesis. J. Cardiovasc. Surg. (2000) 41:415-421.
   Google Scholar
• ROBICSEK F, DAUGHERTY HK, MULLEN DC, MASTERS TN, NARBAY D, SANGER PW: The effect of continued cigarette smoking on the patency of synthetic vascular grafts in Leriche syndrome. J. Thorac. Cardiovasc. Surg. (1975) 70:107-112.
   Google Scholar
• MYERS KA, KING RB, SCOTT DF, JOHNSON N, MORRIS PJ: The effect of smoking on the late patency of arterial reconstructions in the legs. Br. J. Surg. (1978) 65:267-271.
   PubMed Web of Science ®Google Scholar
• CALLE-PASCUAL AL, DURAN A, DIAZ A et al.: Comparison of peripheral arterial reconstruction in diabetic and non-diabetic patients: a prospective clinic-based study. Diabetes Res. Clin Pract. (2001) 53:129-136.
   Web of Science ®Google Scholar
• AHCHONG AK, CHIU KM, WONG MW, HUI HK, YIP AW: Diabetes and the outcome of infrainguinal bypass for critical limb ischaemia. ANZ J. Surg. (2004) 74:129-133.
   Google Scholar
• AKBARI CM, POMPOSELLI FB Jr, GIBBONS GW et al.: Lower extremity revascularization in diabetes: late observations. Arch. Surg. (2000) 135:452-456.
   PubMedGoogle Scholar
• GAHTAN V, HARPAVAT M, ROBERTS AB, KERSTEIN MD: Impact of diabetes mellitus on infrainguinal bypass grafting. J. Diabetes Complications (1998) 12:197-200.
   PubMed Web of Science ®Google Scholar
• MAHARAJ D, OZSVATH KJ, DARLING RC III et al.: Durability of the dorsalis pedis artery reconstruction in diabetics and non-diabetics: is there a difference? Ann. Vasc. Surg. (2002) 16:102-107.
   PubMed Web of Science ®Google Scholar
• PANNETON JM, GLOVICZKI P, BOWER TC, RHODES JM, CANTON LG, TOOMEY BJ: Pedal bypass for limb salvage: impact of diabetes on long-term outcome. Ann. Vasc. Surg. (2000) 14:640-647.
   PubMed Web of Science ®Google Scholar
• ROBINSON KD, SATO DT, GREGORY RT et al.: Long-term outcome after early infrainguinal graft failure. J. Vasc. Surg. (1997) 26:425-437.
   PubMed Web of Science ®Google Scholar
• KARACAGIL S, ALMGREN B, BOWALD S, BERGQVIST D: Comparative analysis of patency, limb salvage and survival in diabetic and non-diabetic patients undergoing infrainguinal bypass surgery. Diabet. Med. (1995) 12:537-541.
   PubMed Web of Science ®Google Scholar
• VIRKKUNEN J, HEIKKINEN M, LEPANTALO M, METSANOJA R, SALENIUS J; FINNVASC STUDY GROUP: Diabetes as an independent risk factor for early postoperative complications in critical limb ischaemia. J. Vasc. Surg. (2004) 40:761-767.
   PubMed Web of Science ®Google Scholar
• WEISS JS, SUMPIO BE: Review of prevalence and outcome of vascular disease in patients with diabetes mellitus. Eur J. Endovasc. Surg. (2006) 31:143-150.
   Google Scholar
• ESPOSITO CJ, POPESCU WM, RINDER HM, SCHWARTZ JJ, SMITH BR, RINDER CS: Increased leukocyte-platelet adhesion in patients with graft occlusion after peripheral vascular surgery. Thromb. Haemost. (2003) 90:1128-1134.
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration. Br. Med. J. (1994) 308:159-168.
   PubMed Web of Science ®Google Scholar
• TANGELDER MJ, LAWSON JA, ALGRA A, EIKELBOOM BC: Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischaemic events after infrainguinal bypass surgery. J. Vasc. Surg. (1999) 30:701-709.
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering committee. Lancet (1996) 348:1329-1339.
   PubMed Web of Science ®Google Scholar
• MATSAGAS M, JAGROOP IA, GEROULAKOS G, MIKHAILIDIS DP: The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin. Appl. Thromb. Hemost. (2003) 9:115-120.
   Google Scholar
• SMOUT JD, MIKHAILIDIS DP, SHENTON BK, STANSBY G: Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin. Appl. Thromb. Hemost. (2004) 10:9-18.
   Google Scholar
• JAGROOP IA, MATSAGAS MI, GEROULAKOS G, MIKHAILIDIS DP: The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets (2004) 15:117-125.
   PubMed Web of Science ®Google Scholar
• PERIPHERAL ARTERIAL DISEASES ANTIPLATELET CONSENSUS GROUP: Antiplatelet therapy in peripheral arterial disease. Consensus Statement. Eur. J. Vasc. Endovasc. Surg. (2003) 26:1-16.
   PubMed Web of Science ®Google Scholar
• KRETSCHMER G, HERBST F, PRAGER M et al.: A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch. Surg. (1992) 127:1112-1115.
   PubMedGoogle Scholar
• Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin study): a randomised trial. Lancet (2000) 355:346-351.
   PubMed Web of Science ®Google Scholar
• WAVE INVESTIGATORS: The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am. Heart J. (2006) 151:1-9.
   PubMed Web of Science ®Google Scholar
• ROBLESS PA, OKONKO D, LINTOTT P, MANSFIELD AO, MIKHAILIDIS DP, STANSBY GP: Increased platelet aggregation and activation in peripheral arterial disease. Eur J. Endovasc. Surg. (2003) 25:16-22.
   Google Scholar
• CHOBANIAN AV, ALEXANDER RW: Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch. Intern. Med. (1996) 156:1952-1956.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS JA, GANOTAKIS ES, JAGROOP IA, MIKHAILIDIS DP, WINDER AF: Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidaemia. Am. J. Hypertens. (1999) 12:673-681.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS JA, MIKHAILIDIS DP, VRENTZOS GE, KALIKAKI A, KAZAKOU I, GANOTAKIS ES: Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin. Appl. Thromb. Hemost. (2005) 11:139-146.
   Google Scholar
• GANOTAKIS ES, PAPADAKIS JA, VRENTZOS GE, MIKHAILIDIS DP: The effects of antihypertensive therapy on haemostatic parameters. Curr. Pharm. Des. (2003) 9:2445-2464.
   Google Scholar
• LAM EY, LANDRY GJ, EDWARDS JM, YEAGER RA, TAYLOR LM, MONETA GL: Risk factors for autogenous infrainguinal bypass occlusion in patients with prosthetic inflow grafts. J. Vasc. Surg. (2004) 39:336-342.
   PubMed Web of Science ®Google Scholar
• OLOJUGBA DH, McCARTHY MJ, REID A et al.: Infrainguinal revascularisation in the era of vein-graft surveillance – do clinical factors influence long-term outcome? Eur. J. Vasc. Endovasc. Surg. (1999) 17:121-128.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ LB, PURUT CM, CRAIG DM, SMITH PK, MOAWAD J, MCCANN RL: Measurement of vascular input impedance in infrainguinal vein grafts. Ann. Vasc. Surg. (1997) 11:35-43.
   PubMed Web of Science ®Google Scholar
• KIM YW, LEE JH, KIM HG, HUH S: Factors affecting the long-term patency of crossover femorofemoral bypass graft. Eur. J. Vasc. Endovasc. Surg. (2005) 30:376-380.
   PubMed Web of Science ®Google Scholar
• DANESH J, LEWINGTON S, THOMPSON SG et al.; FIBRINOGEN STUDIES COLLABORATION: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 294:1799-1809.
   PubMed Web of Science ®Google Scholar
• REINHART WH: Fibrinogen-marker or mediator of vascular disease? Vasc Med. (2003) 8:211-216.
   PubMed Web of Science ®Google Scholar
• CHESHIRE NJ, WOLFE JH, BARRADAS MA, CHAMBLER AW, MIKHAILIDIS DP: Smoking and plasma fibrinogen, lipoprotein(a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur. J. Vasc. Endovasc. Surg. (1996) 11:479-486.
   PubMed Web of Science ®Google Scholar
• WISEMAN S, POWELL J, GREENHALGH R et al.: The influence of smoking and plasma factors on prosthetic graft patency. Eur J. Vasc. Surg. (1990) 4:57-61.
   Google Scholar
• WISEMAN S, KENCHINGTON G, DAIN R et al.: Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. Br. Med. J. (1989) 299:643-646.
   PubMedGoogle Scholar
• HICKS RC, ELLIS M, MIR-HASSEINE R et al.: The influence of fibrinogen concentration on the development of vein graft stenoses. Eur. J. Vasc. Endovasc. Surg. (1995) 9:415-420.
   PubMed Web of Science ®Google Scholar
• LAXDAL E, EIDE GE, WIRSCHING J et al.: Homocysteine levels, haemostatic Risk factors and patency rates after endovascular treatment of the above-knee femoro-popliteal artery. Eur. J. Vasc. Endovasc. Surg. (2004) 28:410-417.
   PubMed Web of Science ®Google Scholar
• BEATTIE DK, SIAN M, GREENHALGH RM, DAVIES AH: Influence of systematic factors on pre-existing intimal hyperplasia and their effect on the outcome of infrainguinal arterial reconstruction with vein. Br. J. Surg. (1999) 86:1441-1447.
   PubMed Web of Science ®Google Scholar
• KAKAFIKA AI, LIBEROPOULOS EN, MIKHAILIDIS DP: Fibrinogen: a predictor of vascular disease. Curr. Pharm. Des. (2007) In press.
   Google Scholar
• RIDKER PM, HENNEKENS CH, BURING JE, RIFAI N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. (2000) 342:836-843.
   PubMed Web of Science ®Google Scholar
• MATZKE S, BIANCARI F, IHLBERG L et al.: Increased preoperative C-reactive protein level as a prognostic factor for postoperative amputation after femoropopliteal bypass surgery for CLI. Ann. Chir. Gynaecol. (2001) 90:19-22.
   PubMedGoogle Scholar
• BIANCARI F, ALBACK A, KANTONEN I, LUTHER M, LEPANTALO M: Predictive factors for adverse outcome of pedal bypasses. Eur. J. Vasc. Endovasc. Surg. (1999) 18:138-143.
   PubMed Web of Science ®Google Scholar
• SCHAEFER EJ, LAMON-FAVA S, JENNER JL et al.: Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA (1994) 271:999-1003.
   PubMed Web of Science ®Google Scholar
• MILIONIS HJ, WINDER AF, MIKHAILIDIS DP: Platelets and lipoprotein(a): a brief overview of their role in the pathogenesis of atherothrombosis. Platelets (1999) 10:277-284.
   PubMed Web of Science ®Google Scholar
• MILIONIS HJ, WINDER AF, MIKHAILIDIS DP: Lipoprotein(a) and stroke. J. Clin. Pathol. (2000) 53:487-496.
   PubMed Web of Science ®Google Scholar
• MILIONIS HJ, DASKALOPOULOU SS, ELISAF M, MIKHAILIDIS DP: The predictive value of lipid markers in vascular disease. Curr Pharm. Des. (2005) 11:2209-2224
   Google Scholar
• CLARKE R, DALY L, ROBINSON K et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. (1991) 324:1149-1155.
   PubMed Web of Science ®Google Scholar
• DE BORST GJ, TANGELDER MJ, ALGRA A et al.; DUTCH BOA (BYPASS ORAL ANTICOAGULANTS OR ASPIRIN) STUDY GROUP: The influence of hyperhomocysteinemia on graft patency after infrainguinal bypass surgery in the Dutch BOA Study. J. Vasc. Surg. (2002) 36:336-340.
   PubMed Web of Science ®Google Scholar
• WOO KS, CHOOK P, LOLIN YI et al.: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation (1997) 96:2542-2544.
   PubMed Web of Science ®Google Scholar
• ROLLAND PH, FRIGGI A, BARLATIER A et al.: Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation (1995) 91:1161-1174.
   PubMed Web of Science ®Google Scholar
• TAYLOR LM Jr, DEFRANG RD, HARRIS EJ Jr, PORTER JM: The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J. Vasc. Surg. (1991) 13:128-136.
   PubMed Web of Science ®Google Scholar
• IRVINE C, WILSON YG, CURRIE IC et al.: Hyperhomocysteinaemia is a risk factor for vein graft stenosis. Eur. J. Vasc. Endovasc. Surg. (1996) 12:304-309.
   PubMed Web of Science ®Google Scholar
• CURRIE IC, WILSON YG, SCOTT J et al.: Homocysteine: an independent risk factor for the failure of vascular intervention. Br. J. Surg. (1996) 83:1238-1241.
   PubMed Web of Science ®Google Scholar
• TSAKIRIS DA, TSCHOPL M, JAGER K, HAEFELI WE, WOLF F MARBET GA: Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis (1999) 142:193-200
   PubMed Web of Science ®Google Scholar
• REFSUM H, NURK E, SMITH AD et al.: The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J. Nutr. (2006) 136(6 Suppl.):1731S-1740S.
   PubMed Web of Science ®Google Scholar
• RASHID ST, SALMAN M, AGARWAL S, HAMILTON G: Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine. Eur. J. Vasc. Endovasc. Surg. (2006) 32:294-299.
   PubMed Web of Science ®Google Scholar
• ALNAEB ME, YOUSSEF F, MIKHAILIDIS DP, HAMILTON G: Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology (2006) 57:65-71.
   PubMed Web of Science ®Google Scholar
• YOUSSEF F, GUPTA P, MIKHAILIDIS DP, HAMILTON G: Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology (2005) 56:279-287.
   PubMed Web of Science ®Google Scholar
• YOUSSEF F, GUPTA P, SEIFALIAN AM, MYINT F, MIKHAILIDIS DP, HAMILTON G: The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology (2004) 55:53-62.
   PubMed Web of Science ®Google Scholar
• ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J. Clin. Pathol. (2004) 57:728-734.
   PubMed Web of Science ®Google Scholar
• ELISAF M, MIKHAILIDIS DP: Statins and renal function. Angiology (2002) 53:493-502.
   PubMed Web of Science ®Google Scholar
• CONTE MS, BANDYK DF, CLOWES AW et al.; PREVENT III INVESTIGATORS: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. (2006) 43:742-751.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, FOSTER JK, KOLM P et al.: Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Am. Heart J. (2006): 152:770-776.
   PubMed Web of Science ®Google Scholar
• WANG GJ, SUI XX, SIMOSA HF, JAIN MK, ALTIERI DC, CONTE MS: Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler. Thromb. Vasc. Biol. (2005) 25:2081-2087.
   PubMed Web of Science ®Google Scholar
• SCHACHNER T, ZOU Y, OBERHUBER A et al.: Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann. Thorac. Surg. (2004) 77:1580-1585.
   PubMed Web of Science ®Google Scholar
• CARAGIANNOS C, ABUL-KHOUDOUD OR, DERIJK W et al.: Rapamycin-coated expanded polytetrafluorethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. J. Vasc. Surg. (2005) 42:980-988.
   PubMed Web of Science ®Google Scholar
• CONTE MS, BANDYK DF, CLOWES AW, MONETA GL, NAMINI H, SEELY L: Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J. Vasc. Surg. (2005) 42:456-464.
   PubMed Web of Science ®Google Scholar
• DASKALOPOULOU SS, DASKALOPOULOS ME, LIAPIS CD, MIKHAILIDIS DP: Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med. Chem. (2005) 12:443-452.
   Google Scholar
• NORGREN L, HIATT WR, DORMANDY JA, NEHLER MR, HARRIS KA, FOWKES FG; ON BEHALF OF THE TASC II WORKING GROUP: Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur. J. Vasc. Endovasc. Surg. (2007) 33:S1-S75.
   Google Scholar
• ROBLESS P, MIKHAILIDIS DP, STANSBY G: Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br. J. Surg. (2001) 88:787-800.
   PubMed Web of Science ®Google Scholar
• PARASKEVAS KI, LIAPIS CD, HAMILTON G, MIKHAILIDIS DP: Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur. J. Vasc. Endovasc. Surg. (2006) 32:286-293.
   PubMed Web of Science ®Google Scholar
• ALNAEB ME, ALOBAID N, SEIFALIAN AM, MIKHAILIDIS DP, HAMILTON G: Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann. Vasc. Surg. (2006) 20:696-705.
   PubMed Web of Science ®Google Scholar
• LASTRA-GONZALEZ G, MANRIQUE CM, GOVINDARAJAN G, WHALEY-CONNELL A, SOWERS JR: Insight into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opin. Pharmacother. (2005) 6:2209-2221.
   PubMed Web of Science ®Google Scholar
• PRASAD K: C-reactive protein (CRP)-lowering agents. Cardiovasc. Drug Rev. (2006) 24:33-50.
   Google Scholar
• RIZOS E, KOSTOULA A, ELISAF M, MIKHAILIDIS DP: Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology (2002) 53:273-277.
   PubMed Web of Science ®Google Scholar
• TSIMIHODIMOS V, MILTIADOUS G, DASKALOPOULOU SS, MIKHAILIDIS DP, ELISAF MS: Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. (2005) 3:87-98.
   Google Scholar